Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies

European Journal of Cancer

Volumn 46, Issue 7, 2010, Pages 1204-1210

  Gril, Brunilde ^a   Evans, Lynda ^a   Palmieri, Diane ^a   Steeg, Patricia S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Brain; Breast; Lung; Metastases

Indexed keywords

BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN 4; CAPECITABINE; CARBOPLATIN; COLLAGEN TYPE 1; CORTICOSTEROID; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBRONECTIN; LAMININ; LAPATINIB; LYMPHOID ENHANCER FACTOR 1; NERVE CELL ADHESION MOLECULE; PEMETREXED; SUNITINIB; TRASTUZUMAB; VATALANIB; VITRONECTIN RECEPTOR; WNT PROTEIN; WNT3A PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM METASTASIS; DISTANT METASTASIS; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MORBIDITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

ADULT; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTEGRINS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; TRANSLATIONAL RESEARCH;

EID: 77950553945     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.02.033     Document Type: Article

References (65)

1. Weil R., Palmieri D., Bronder J., Stark A., and Steeg P. Breast cancer metastasis to the central nervous system. Am J Pathol 167 (2005) 913-920
2. Patel R., and Mehta M. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13 6 (2007) 1675-1683
3. Castrucci W.A., and Knisely J.P. An update on the treatment of CNS metastases in small cell lung cancer. Cancer J 14 3 (2008) 138-146
4. Schwer A.L., and Gaspar L.E. Update in the treatment of brain metastases from lung cancer. Clin Lung Cancer 8 3 (2006) 180-186
5. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. New Engl J Med 357 7 (2007) 664-672
6. Lester J.F., MacBeth F.R., and Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. Int J Radiat Oncol Biol Phys 63 3 (2005) 690-694
7. Grinberg-Rashi H., Ofek E., Perelman M., et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 15 5 (2009) 1755-1761
8. Barnholtz-Sloan J.S., Sloan A.E., and Davis F.G. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 14 (2004) 2865-2872
9. Stemmler H.J., and Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13 7 (2008) 739-750
10. Kesari S., and Batchelor T. Leptomeningeal metastases. Neurol Clin 21 (2003) 25-66
11. Lin N.U., Claus E., Sohl J., Razzak A.R., Arnaout A., and Winer E.P. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113 10 (2008) 2638-2645
12. Lin N.U., and Winer E.P. Brain metastases: the HER2 paradigm. Clin Cancer Res 13 6 (2007) 1648-1655
13. Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17 6 (2006) 935-944
14. Bendell J., Domchek S., Burstein H., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 (2003) 2972-2977
15. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24 36 (2006) 5658-5663
16. Shmueli E., Wigler N., and Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40 3 (2004) 379-382
17. Clayton A., Danson S., Jolly S., et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Brit J Cancer 91 (2004) 639-643
18. Lower E., Blau R., Bismayer J., et al. Increased brain metastasis detected in metastatic breast cancer patients receiving herceptin. Breast Cancer Res Treat 69 (2001) 271 [Abstract 351]
19. Kikuchi T., Daigo Y., Ishikawa N., et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 28 4 (2006) 799-805
20. Saito N., Hatori T., Aoki K., et al. Dynamics of global gene expression changes during brain metastasis formation. Neuropathology 29 4 (2009) 389-397
21. Derycke L.D., and Bracke M.E. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48 5-6 (2004) 463-476
22. Nakashima T., Huang C., Liu D., et al. Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Brit J Cancer 88 11 (2003) 1727-1733
23. Perotti A., Sessa C., Mancuso A., et al. Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 20 4 (2009) 741-745
24. Beasley G.M., McMahon N., Sanders G., et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 115 20 (2009) 4766-4774
25. Nguyen D.X., Chiang A.C., Zhang X.H., et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138 1 (2009) 51-62
26. Xu H.T., Wei Q., Liu Y., et al. Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer. Ann Surg Oncol 14 11 (2007) 3251-3259
27. Raz D.J., Ray M.R., Kim J.Y., et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 14 17 (2008) 5565-5570
28. Bos P.D., Zhang X.H., Nadal C., et al. Genes that mediate breast cancer metastasis to the brain. Nature 459 7249 (2009) 1005-1009
29. Minn A.J., Gupta G.P., Padua D., et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104 16 (2007) 6740-6745
30. Palmieri D., Fitzgerald D., Shreeve S.M., et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res 7 9 (2009) 1438-1445
31. Mathupala S.P., Ko Y.H., and Pedersen P.L. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25 34 (2006) 4777-4786
32. Peng S.Y., Lai P.L., Pan H.W., Hsiao L.P., and Hsu H.C. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19 4 (2008) 1045-1053
33. Rho M., Kim J., Jee C.D., et al. Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. Anticancer Res 27 1A (2007) 251-258
34. Chen E.I., Hewel J., Krueger J.S., et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res 67 4 (2007) 1472-1486
35. Felding-Habermann B., O'Toole T., Smith J., et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 98 (2001) 1853-1858
36. Lorger M., Krueger J.S., O'Neal M., Staflin K., and Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc Natl Acad Sci USA 106 26 (2009) 10666-10671
37. Yoshimasu T., Sakurai T., Oura S., et al. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci 95 2 (2004) 142-148
38. Palmieri D., Bronder J.L., Herring J.M., et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 67 9 (2007) 4190-4198
39. Gril B., Palmieri D., Bronder J.L., et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100 15 (2008) 1092-1103
40. Geyer C., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. New Engl J Med 355 (2006) 2733-2743
41. Cameron D., Casey M., Press M., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112 3 (2008) 533-543
42. Lin N., Carey L., Liu M., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol 24 18S (2006) 503
43. Lin N.U., Dieras V., Paul D., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15 4 (2009) 1452-1459
44. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., and Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3 1 (2002) 53-57
45. Kusters B., Leenders W.P., Wesseling P., et al. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 62 2 (2002) 341-345
46. Leenders W., Kusters B., Verrijp K., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10 (2004) 6222-6230
47. Fitzgerald D., Palmieri D., Hua E., et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metast 25 (2008) 799-810
48. Carbonell W.S., Ansorge O., Sibson N., and Muschel R. The vascular basement membrane as "soil" in brain metastasis. PLoS One 4 6 (2009) e5857
49. Folkman J. What is the evidence that tumors are angiogenesis-dependent?. J Natl Cancer Inst 82 (1990) 4-6
50. Kim L., Huang S., Lu W., Lev D.C., and Price J. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis 21 (2004) 107-118
51. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 3 (2009) 232-239
52. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 3 (2009) 220-231
53. Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27 31 (2009) 5255-5261
54. Chen A.M., Jahan T.M., Jablons D.M., Garcia J., and Larson D.A. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 109 8 (2007) 1668-1675
55. Omuro A.M., Kris M.G., Miller V.A., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103 11 (2005) 2344-2348
56. Eichler A.F., and Loeffler J.S. Multidisciplinary management of brain metastases. Oncologist 12 7 (2007) 884-898
57. Baschnagel A., Russo A., Burgan W.E., et al. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 8 6 (2009) 1589-1595
58. Palmieri D., Lockman P.R., Thomas F.C., et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 15 19 (2009) 6148-6157
59. Clark G., Sledge G.W., Osborne C., and McGuire W. Survival from first recurrence. Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5 (1987) 55-61
60. Slimane K., Andre F., Delaloge S., et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 15 11 (2004) 1640-1644
61. Evans A., James J., Cornford E., et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol 16 (2004) 345-349
62. Miller K., Weathers T., Hanley L., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14 (2003) 1072-1077
63. Carey L.A., Ewend M.G., Metzger R., et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 88 3 (2004) 273-280
64. Hicks D., Short S., Prescott N., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6 and over-express Her-2 or EGFR. Am J Surg Pathol 30 (2006) 1097-1104
65. Sezgin C., Gokmen E., Esassolak M., Ozdemir N., and Goker E. Risk factors for central nervous system metastasis in patients with metastatic breast cancer. Med Oncol 24 2 (2007) 155-161